Stay updated on Johnson & Johnson's Q2 earnings as it faces tariff threats, MedTech challenges, and legal risks.

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Johnson & Johnson ( JNJ 0.01%) has been a leading healthcare company in the world for decades, and it's one of the most ...

The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage ...

Market reaction to recent readouts from Compass Pathways and Beckley Psytech/atai in treatment-resistant depression speaks to ...

The three philanthropists devoted themselves and their resources to important causes during lifetimes of service to Palm ...